Almost half of all serious bacterial infections in newborn babies are caused by group B streptococcus (GBS). These bacteria are carried by around one in four women. Professor Gunnar Lindahl and Dr Thomas Areschoug have now developed a possible vaccine against the infection. The vaccine became basis of the pharmaceutical company Minervax. The company is now based in Denmark.
Develop a novel vaccine candidate against Group B Streptococci (GBS)
Founded by Professor Gunnar Lindahl with research team.
Portfolio company since 2010.
Portfolio Manager LU Holding:
christine [dot] widstrand [at] innovation [dot] lu [dot] se (Christine Widstrand), phone +46 70 928 63 78